<?xml version="1.0" encoding="UTF-8"?>
<p id="p0130">Repurposing of known drugs can provide an accelerated route to approval, which is likely the only option to address the current COVID-19 crisis. Small molecules like ebselen or carmofur are M
 <sup>pro</sup> inhibitors with anti-SARS-CoV-2 activity in cells;
 <xref rid="b0395" ref-type="bibr">
  <sup>79</sup>
 </xref> however, their thiol reactivity might prove challenging. Repurposing approved protease inhibitors is an alternative approach.
 <xref rid="b0510" ref-type="bibr">
  <sup>102</sup>
 </xref> Attempts to repurpose the approved combination of HIV protease inhibitors, ritonavir and lopinavir, was unsuccessful in clinical studies, which is not entirely unexpected, given the differences between the proteases of HIV and SARS-CoV-2.
 <xref rid="b0535" ref-type="bibr">
  <sup>107</sup>
 </xref>
</p>
